Drug repurposing to improve treatment of rheumatic autoimmune inflammatory diseases
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Drug repurposing to improve treatment of rheumatic autoimmune inflammatory diseases
Authors
Keywords
-
Journal
Nature Reviews Rheumatology
Volume 16, Issue 1, Pages 32-52
Publisher
Springer Science and Business Media LLC
Online
2019-12-16
DOI
10.1038/s41584-019-0337-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Drug-induced diabetes type 2: In silico study involving class B GPCRs
- (2019) Dorota Latek et al. PLoS One
- Chromatin interactions reveal novel gene targets for drug repositioning in rheumatic diseases
- (2019) Paul Martin et al. ANNALS OF THE RHEUMATIC DISEASES
- deepDR: A network-based deep learning approach to in silico drug repositioning
- (2019) Xiangxiang Zeng et al. BIOINFORMATICS
- Low-dose cyclosporine for active lupus nephritis: a dose titration approach
- (2019) Kittiwan Sumethkul et al. CLINICAL RHEUMATOLOGY
- Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study
- (2019) Josef S Smolen et al. LANCET
- Exploiting machine learning for end-to-end drug discovery and development
- (2019) Sean Ekins et al. NATURE MATERIALS
- Applications of machine learning in drug discovery and development
- (2019) Jessica Vamathevan et al. NATURE REVIEWS DRUG DISCOVERY
- A genetics-led approach defines the drug target landscape of 30 immune-related traits
- (2019) Hai Fang et al. NATURE GENETICS
- Machine learning approaches to predict lupus disease activity from gene expression data
- (2019) Brian Kegerreis et al. Scientific Reports
- A paradigm shift in medicine: A comprehensive review of network-based approaches
- (2019) Federica Conte et al. Biochimica et Biophysica Acta-Gene Regulatory Mechanisms
- Predicting serious rare adverse reactions of novel chemicals
- (2018) Aleksandar Poleksic et al. BIOINFORMATICS
- Inventing new therapies without reinventing the wheel: the power of drug repurposing
- (2018) Andreas Papapetropoulos et al. BRITISH JOURNAL OF PHARMACOLOGY
- Hydroxychloroquine: An old drug with new relevance
- (2018) E. A. SHIPPEY et al. CLEVELAND CLINIC JOURNAL OF MEDICINE
- Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1/2 trial
- (2018) Zhi-Wei Lai et al. LANCET
- Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial
- (2018) Daniel J Wallace et al. LANCET
- OUP accepted manuscript
- (2018) RHEUMATOLOGY
- Efficacy and Safety of Atacicept in Patients With Systemic Lupus Erythematosus
- (2018) Joan T. Merrill et al. Arthritis & Rheumatology
- Exploration of the Anti-Inflammatory Drug Space Through Network Pharmacology: Applications for Drug Repurposing
- (2018) Guillermo de Anda-Jáuregui et al. Frontiers in Physiology
- Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial
- (2018) Joan T Merrill et al. ANNALS OF THE RHEUMATIC DISEASES
- Lessons learned from the failure of several recent trials with biologic treatment in systemic lupus erythematosus
- (2018) Zdenka Hruskova et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study
- (2018) Ronald F van Vollenhoven et al. LANCET
- Leflunomide versus cyclophosphamide in the induction treatment of proliferative lupus nephritis in Chinese patients: a randomized trial
- (2018) Minfang Zhang et al. CLINICAL RHEUMATOLOGY
- Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial
- (2018) Désirée van der Heijde et al. LANCET
- Identification of alterations in macrophage activation associated with disease activity in systemic lupus erythematosus
- (2018) Adam C. Labonte et al. PLoS One
- The ReFRAME library as a comprehensive drug repurposing library and its application to the treatment of cryptosporidiosis
- (2018) Jeff Janes et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: 16 Week Results of a Phase 3 Randomized, Double-Blind, Placebo Controlled Trial in Patients with Prior Inadequate Response or Intolerance to Tumor Necrosis Factor
- (2018) Atul Deodhar et al. Arthritis & Rheumatology
- Safety and Efficacy of Golimumab Administered Intravenously in Adults with Ankylosing Spondylitis: Results through Week 28 of the GO-ALIVE Study
- (2017) Atul Deodhar et al. JOURNAL OF RHEUMATOLOGY
- The Drug Repurposing Hub: a next-generation drug library and information resource
- (2017) Steven M Corsello et al. NATURE MEDICINE
- The genetics revolution in rheumatology: large scale genomic arrays and genetic mapping
- (2017) Stephen Eyre et al. Nature Reviews Rheumatology
- Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis
- (2017) Philip Mease et al. NEW ENGLAND JOURNAL OF MEDICINE
- ADReCS-Target: target profiles for aiding drug safety research and application
- (2017) Li-Hong Huang et al. NUCLEIC ACIDS RESEARCH
- PharmMapper 2017 update: a web server for potential drug target identification with a comprehensive target pharmacophore database
- (2017) Xia Wang et al. NUCLEIC ACIDS RESEARCH
- Drug Repositioning Strategies for the Identification of Novel Therapies for Rheumatic Autoimmune Inflammatory Diseases
- (2017) Amrie C. Grammer et al. RHEUMATIC DISEASE CLINICS OF NORTH AMERICA
- Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA
- (2017) Désirée van der Heijde et al. RHEUMATOLOGY
- Transancestral mapping and genetic load in systemic lupus erythematosus
- (2017) Carl D. Langefeld et al. Nature Communications
- Phenome-Wide Association Study of Rheumatoid Arthritis Subgroups Identifies Association Between Seronegative Disease and Fibromyalgia
- (2017) Jayanth Doss et al. Arthritis & Rheumatology
- Safety and Efficacy of Intravenous Golimumab in Patients With Active Psoriatic Arthritis
- (2017) Arthur Kavanaugh et al. Arthritis & Rheumatology
- Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study
- (2017) William Stohl et al. Arthritis & Rheumatology
- Enhancing the Promise of Drug Repositioning through Genetics
- (2017) Jayne-Louise E. Pritchard et al. Frontiers in Pharmacology
- A standard database for drug repositioning
- (2017) Adam S. Brown et al. Scientific Data
- Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3)
- (2016) Christopher J Edwards et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial
- (2016) Daniel J Wallace et al. ANNALS OF THE RHEUMATIC DISEASES
- Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1
- (2016) Philip J Mease et al. ANNALS OF THE RHEUMATIC DISEASES
- Gene expression inference with deep learning
- (2016) Yifei Chen et al. BIOINFORMATICS
- QUADrATiC: scalable gene expression connectivity mapping for repurposing FDA-approved therapeutics
- (2016) Paul G. O’Reilly et al. BMC BIOINFORMATICS
- A genomics-based systems approach towards drug repositioning for rheumatoid arthritis
- (2016) Rong Xu et al. BMC GENOMICS
- SDTNBI: an integrated network and chemoinformatics tool for systematic prediction of drug–target interactions and drug repositioning
- (2016) Zengrui Wu et al. BRIEFINGS IN BIOINFORMATICS
- A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial
- (2016) M. Cutolo et al. JOURNAL OF RHEUMATOLOGY
- A critical review of clinical trials in systemic lupus erythematosus
- (2016) M A Mahieu et al. LUPUS
- Drug repositioning in SLE: crowd-sourcing, literature-mining and Big Data analysis
- (2016) A C Grammer et al. LUPUS
- Can you teach old drugs new tricks?
- (2016) Nicola Nosengo NATURE
- Genome-wide association meta-analysis in Chinese and European individuals identifies ten new loci associated with systemic lupus erythematosus
- (2016) David L Morris et al. NATURE GENETICS
- High-density genotyping of immune-related loci identifies new SLE risk variants in individuals with Asian ancestry
- (2016) Celi Sun et al. NATURE GENETICS
- Beyond pan-B-cell-directed therapy — new avenues and insights into the pathogenesis of SLE
- (2016) Thomas Dörner et al. Nature Reviews Rheumatology
- Baricitinib in Patients with Refractory Rheumatoid Arthritis
- (2016) Mark C. Genovese et al. NEW ENGLAND JOURNAL OF MEDICINE
- New Treatment Guidelines for Sjögren's Disease
- (2016) Frederick B. Vivino et al. RHEUMATIC DISEASE CLINICS OF NORTH AMERICA
- Network-based in silico drug efficacy screening
- (2016) Emre Guney et al. Nature Communications
- ‘RE:fine drugs’: an interactive dashboard to access drug repurposing opportunities
- (2016) Soheil Moosavinasab et al. Database-The Journal of Biological Databases and Curation
- The Efficacy and Safety of Clazakizumab, an Anti-Interleukin-6 Monoclonal Antibody, in a Phase IIb Study of Adults With Active Psoriatic Arthritis
- (2016) Philip J. Mease et al. Arthritis & Rheumatology
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Treatment With Sirukumab (CNTO 136) in Patients With Active Lupus Nephritis
- (2016) Brad H. Rovin et al. Arthritis & Rheumatology
- Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study
- (2015) J T Merrill et al. ANNALS OF THE RHEUMATIC DISEASES
- A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE)
- (2015) Kenneth C Kalunian et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study
- (2015) D A Isenberg et al. ANNALS OF THE RHEUMATIC DISEASES
- Drug repositioning and repurposing: terminology and definitions in literature
- (2015) Joris Langedijk et al. DRUG DISCOVERY TODAY
- Longterm (52-week) Results of a Phase III Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis
- (2015) A. Kavanaugh et al. JOURNAL OF RHEUMATOLOGY
- Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2015) Iain B McInnes et al. LANCET
- Lupus eritematoso cutáneo subagudo inducido por golimumab
- (2015) Gonzalo Blasco-Morente et al. MEDICINA CLINICA
- Genetic association analyses implicate aberrant regulation of innate and adaptive immunity genes in the pathogenesis of systemic lupus erythematosus
- (2015) James Bentham et al. NATURE GENETICS
- Genetics of ankylosing spondylitis—insights into pathogenesis
- (2015) Matthew A. Brown et al. Nature Reviews Rheumatology
- Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis
- (2015) Dominique Baeten et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis
- (2015) Mark Lebwohl et al. NEW ENGLAND JOURNAL OF MEDICINE
- STITCH 5: augmenting protein–chemical interaction networks with tissue and affinity data
- (2015) Damian Szklarczyk et al. NUCLEIC ACIDS RESEARCH
- BindingDB in 2015: A public database for medicinal chemistry, computational chemistry and systems pharmacology
- (2015) Michael K. Gilson et al. NUCLEIC ACIDS RESEARCH
- The SIDER database of drugs and side effects
- (2015) Michael Kuhn et al. NUCLEIC ACIDS RESEARCH
- Identification of small-molecule inhibitors of calcineurin-NFATc signaling that mimic the PxIxIT motif of calcineurin binding partners
- (2015) Minos-Timotheos Matsoukas et al. Science Signaling
- Etanercept in refractory lupus arthritis: An observational study
- (2015) Josefina Cortés-Hernández et al. SEMINARS IN ARTHRITIS AND RHEUMATISM
- Identification of small-molecule inhibitors of calcineurin-NFATc signaling that mimic the PxIxIT motif of calcineurin binding partners
- (2015) Minos-Timotheos Matsoukas et al. Science Signaling
- Safety and Efficacy of Atacicept in Combination With Rituximab for Reducing the Signs and Symptoms of Rheumatoid Arthritis: A Phase II, Randomized, Double-Blind, Placebo-Controlled Pilot Trial
- (2015) R. F. van Vollenhoven et al. Arthritis & Rheumatology
- Apremilast in Patients With Active Rheumatoid Arthritis: A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study
- (2015) Mark C. Genovese et al. Arthritis & Rheumatology
- Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases
- (2015) K. D. Rainsford et al. INFLAMMOPHARMACOLOGY
- Lupus Nephritis: The Evolving Role of Novel Therapeutics
- (2014) Brad H. Rovin et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Abatacept treatment reduces disease activity in early primary Sjögren's syndrome (open-label proof of concept ASAP study)
- (2014) P M Meiners et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial)
- (2014) David Isenberg et al. ANNALS OF THE RHEUMATIC DISEASES
- Sarilumab for the treatment of ankylosing spondylitis: results of a Phase II, randomised, double-blind, placebo-controlled study (ALIGN)
- (2014) Joachim Sieper et al. ANNALS OF THE RHEUMATIC DISEASES
- Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS)
- (2014) Denis Poddubnyy et al. ANNALS OF THE RHEUMATIC DISEASES
- Mantra 2.0: an online collaborative resource for drug mode of action and repurposing by network analysis
- (2014) D. Carrella et al. BIOINFORMATICS
- Anti-TNF therapy: past, present and future
- (2014) C. Monaco et al. INTERNATIONAL IMMUNOLOGY
- Efficacy and safety of tacrolimus for lupus nephritis: a placebo-controlled double-blind multicenter study
- (2014) Nobuyuki Miyasaka et al. Modern Rheumatology
- Efficacy and safety of tacrolimus for induction therapy in patients with active lupus nephritis
- (2014) Satoshi Takahashi et al. Modern Rheumatology
- Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials
- (2014) Richard G. Langley et al. NEW ENGLAND JOURNAL OF MEDICINE
- ADReCS: an ontology database for aiding standardization and hierarchical classification of adverse drug reaction terms
- (2014) Mei-Chun Cai et al. NUCLEIC ACIDS RESEARCH
- The efficacy of topical 0.05 % cyclosporine A in patients with dry eye disease associated with Sjögren’s syndrome
- (2014) Hülya Devecı et al. INTERNATIONAL OPHTHALMOLOGY
- Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials
- (2013) Joachim Sieper et al. ANNALS OF THE RHEUMATIC DISEASES
- Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA)
- (2013) P J Mease et al. ANNALS OF THE RHEUMATIC DISEASES
- Rituximab Therapy for Primary Sjögren's Syndrome: An Open-Label Clinical Trial and Mechanistic Analysis
- (2013) E. William St.Clair et al. ARTHRITIS AND RHEUMATISM
- Integrative relational machine-learning for understanding drug side-effect profiles
- (2013) Emmanuel Bresso et al. BMC BIOINFORMATICS
- The Electronic Medical Records and Genomics (eMERGE) Network: past, present and future
- (2013) Omri Gottesman et al. GENETICS IN MEDICINE
- Efficacy and Safety of Belimumab in Patients with Rheumatoid Arthritis: A Phase II, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study
- (2013) W. Stohl et al. JOURNAL OF RHEUMATOLOGY
- Development and evaluation of an ensemble resource linking medications to their indications
- (2013) Wei-Qi Wei et al. JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION
- Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial
- (2013) Iain B McInnes et al. LANCET
- Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial
- (2013) Cem Gabay et al. LANCET
- Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial
- (2013) Gerd R Burmester et al. LANCET
- Clinical outcomes and safety of rituximab treatment for patients with systemic lupus erythematosus (SLE) – results from a nationwide cohort in Germany (GRAID)
- (2013) M Witt et al. LUPUS
- Characterization of drug-induced transcriptional modules: towards drug repositioning and functional understanding
- (2013) M. Iskar et al. Molecular Systems Biology
- Genetics of rheumatoid arthritis contributes to biology and drug discovery
- (2013) Yukinori Okada et al. NATURE
- Systematic comparison of phenome-wide association study of electronic medical record data and genome-wide association study data
- (2013) Joshua C Denny et al. NATURE BIOTECHNOLOGY
- A genome-wide association study in Han Chinese identifies a susceptibility locus for primary Sjögren's syndrome at 7q11.23
- (2013) Yongzhe Li et al. NATURE GENETICS
- Variants at multiple loci implicated in both innate and adaptive immune responses are associated with Sjögren's syndrome
- (2013) Christopher J Lessard et al. NATURE GENETICS
- Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci
- (2013) Adrian Cortes et al. NATURE GENETICS
- Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1)
- (2012) Joachim Sieper et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab study
- (2012) Brad H. Rovin et al. ARTHRITIS AND RHEUMATISM
- Relating drug-protein interaction network with drug side effects
- (2012) S. Mizutani et al. BIOINFORMATICS
- DTome: a web-based tool for drug-target interactome construction
- (2012) Jingchun Sun et al. BMC BIOINFORMATICS
- Adalimumab
- (2012) Celeste B. Burness et al. DRUGS
- Large-scale prediction of adverse drug reactions using chemical, biological, and phenotypic properties of drugs
- (2012) Mei Liu et al. JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION
- NCATS launches drug repurposing program
- (2012) Malorye Allison NATURE BIOTECHNOLOGY
- Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis
- (2012) Kim A. Papp et al. NEW ENGLAND JOURNAL OF MEDICINE
- Interleukin-1 Inhibition and Fatigue in Primary Sjögren's Syndrome – A Double Blind, Randomised Clinical Trial
- (2012) Katrine Brække Norheim et al. PLoS One
- A randomized placebo-controlled trial of methotrexate in psoriatic arthritis
- (2012) Gabrielle H. Kingsley et al. RHEUMATOLOGY
- Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial
- (2012) Ellen M Ginzler et al. ARTHRITIS RESEARCH & THERAPY
- Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study
- (2011) I.-H. Song et al. ANNALS OF THE RHEUMATIC DISEASES
- A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus
- (2011) Richard Furie et al. ARTHRITIS AND RHEUMATISM
- Predicting drug side-effect profiles: a chemical fragment-based approach
- (2011) Edouard Pauwels et al. BMC BIOINFORMATICS
- Efficacy and safety of the human anti-IL-1beta monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, phase II, dose-finding study
- (2011) Rieke Alten et al. BMC MUSCULOSKELETAL DISORDERS
- Lack of efficacy of abatacept in axial spondylarthropathies refractory to tumor-necrosis-factor inhibition
- (2011) Fernando Kemta Lekpa et al. JOINT BONE SPINE
- PREDICT: a method for inferring novel drug indications with application to personalized medicine
- (2011) A. Gottlieb et al. Molecular Systems Biology
- Mycophenolate versus Azathioprine as Maintenance Therapy for Lupus Nephritis
- (2011) Mary Anne Dooley et al. NEW ENGLAND JOURNAL OF MEDICINE
- 50th anniversary of the discovery of ibuprofen: an interview with Dr Stewart Adams
- (2011) Gayle M. Halford et al. PLATELETS
- Replication of GWAS-identified systemic lupus erythematosus susceptibility genes affirms B-cell receptor pathway signalling and strengthens the role of IRF5 in disease susceptibility in a Northern European population
- (2011) T. M. Jarvinen et al. RHEUMATOLOGY
- The NCGC Pharmaceutical Collection: A Comprehensive Resource of Clinically Approved Drugs Enabling Repurposing and Chemical Genomics
- (2011) R. Huang et al. Science Translational Medicine
- Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID)
- (2011) Hans-Peter Tony et al. ARTHRITIS RESEARCH & THERAPY
- The efficacy and safety of tacrolimus in rheumatoid arthritis
- (2011) Shouma Dutta et al. Therapeutic Advances in Musculoskeletal Disease
- The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: Results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial
- (2010) J. T. Merrill et al. ARTHRITIS AND RHEUMATISM
- Tocilizumab in systemic lupus erythematosus: Data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study
- (2010) Gabor G. Illei et al. ARTHRITIS AND RHEUMATISM
- Ustekinumab
- (2010) Oya Cingoz mAbs
- Network medicine: a network-based approach to human disease
- (2010) Albert-László Barabási et al. NATURE REVIEWS GENETICS
- Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis
- (2010) W. Hueber et al. Science Translational Medicine
- Apremilast: a novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseases
- (2010) Georg Schett et al. Therapeutic Advances in Musculoskeletal Disease
- Blocking Interleukin-1 in Rheumatic Diseases
- (2009) Raphaela Goldbach-Mansky Annals of the New York Academy of Sciences
- Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trial
- (2009) Joan T. Merrill et al. ARTHRITIS AND RHEUMATISM
- Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial
- (2009) Josef S Smolen et al. LANCET
- The efficacy and safety of leflunomide therapy in lupus nephritis by repeat kidney biopsy
- (2009) F. S. Zhang et al. RHEUMATOLOGY INTERNATIONAL
- Reduction of fatigue in Sjogren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study
- (2008) S Dass et al. ANNALS OF THE RHEUMATIC DISEASES
- Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: Findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study
- (2008) Edward Keystone et al. ARTHRITIS AND RHEUMATISM
- Steroid-sparing effects of methotrexate in systemic lupus erythematosus: A double-blind, randomized, placebo-controlled trial
- (2008) Paul R. Fortin et al. ARTHRITIS AND RHEUMATISM
- Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial
- (2008) Josef S Smolen et al. LANCET
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
- (2008) Craig L Leonardi et al. LANCET
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
- (2008) Kim A Papp et al. LANCET
- Induction treatment of proliferative lupus nephritis with leflunomide combined with prednisone: a prospective multi-centre observational study
- (2008) HY Wang et al. LUPUS
- Leflunomide-induced subacute cutaneous lupus erythematosus with erythema multiforme-like lesions
- (2008) AV Marzano et al. LUPUS
- Drug Target Identification Using Side-Effect Similarity
- (2008) M. Campillos et al. SCIENCE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now